Theratechnologies Inc. (THTX)
NASDAQ: THTX · Real-Time Price · USD
1.790
+0.130 (7.83%)
Dec 20, 2024, 4:00 PM EST - Market closed
Theratechnologies Revenue
Theratechnologies had revenue of $22.60M in the quarter ending August 31, 2024, with 8.37% growth. This brings the company's revenue in the last twelve months to $84.32M, up 5.75% year-over-year. In the fiscal year ending November 30, 2023, Theratechnologies had annual revenue of $81.76M with 2.13% growth.
Revenue (ttm)
$84.32M
Revenue Growth
+5.75%
P/S Ratio
n/a
Revenue / Employee
$818,602
Employees
103
Market Cap
79.98M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Nov 30, 2023 | 81.76M | 1.71M | 2.13% |
Nov 30, 2022 | 80.06M | 10.23M | 14.66% |
Nov 30, 2021 | 69.82M | 3.77M | 5.71% |
Nov 30, 2020 | 66.05M | 2.84M | 4.49% |
Nov 30, 2019 | 63.22M | 18.00M | 39.81% |
Nov 30, 2018 | Pro | Pro | Pro |
Nov 30, 2017 | Pro | Pro | Pro |
Nov 30, 2016 | Pro | Pro | Pro |
Nov 30, 2015 | Pro | Pro | Pro |
Nov 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTHTX News
- 3 days ago - Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment - GlobeNewsWire
- 11 days ago - Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA - GlobeNewsWire
- 12 days ago - Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer - GlobeNewsWire
- 17 days ago - Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada - GlobeNewsWire
- 18 days ago - Theratechnologies Announces Resumed Production of EGRIFTA SV® - GlobeNewsWire
- 19 days ago - Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec - GlobeNewsWire
- 25 days ago - Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review - GlobeNewsWire
- 2 months ago - Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV - GlobeNewsWire